1 Li S, Young KH, Medeiros LJ (2018) Diffuse large B-cell lymphoma. Pathology 50:74-87
2 Miyazaki K (2016) Treatment of Diffuse Large B-Cell Lymphoma. J Clin Exp Hematop 56:79-88
3 Boris K, Gerhard H, Michael PJCT, Research (2015) Management of diffuse large B-cell lymphoma (DLBCL). 165:271
4 Cardinale D, Colombo A, Bacchiani G et al (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981-1988
5 Linschoten M, Teske AJ, Baas AF et al (2017) Truncating Titin ( TTN) Variants in Chemotherapy-Induced Cardiomyopathy. 23:476-479
6 Ewer MS, Ewer SM, %J Nature Reviews Cardiology (2015) Cardiotoxicity of anticancer treatments. 12:547-558
7 Laursen AH, Thune JJ, Hutchings M, Hasbak P, Ripa RSJCPFI (2017) 123 I-MIBG imaging for detection of anthracycline-induced cardiomyopathy. 38
8 Mcmurray JJV, Adamopoulos S, Anker SD et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. 14:803–869
9 Dutta T, Spevack DM, Aronow WS (2019) The left ventricular ejection fraction: new insights into an old parameter. Hosp Pract (1995). 10.1080/21548331.2019.1687247:1-10
10 Ong G, Brezden-Masley C, Dhir V et al (2018) Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy. Int J Cardiol 261:228-233
11 Virani SA, Brezden-Masley C, Clarke B et al (2016) Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. 32:831-841
12 Zamorano JL, Lancellotti P, Muñoz DR et al (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. 74:1193
13 Seraphim A, Westwood M, Bhuva AN et al (2019) Advanced Imaging Modalities to Monitor for Cardiotoxicity. Curr Treat Options Oncol 20:73
14 Markman TM, Ruble K, Loeb D et al (2017) Electrophysiological effects of anthracyclines in adult survivors of pediatric malignancy. Pediatr Blood Cancer 64
15 Yu AF, Manrique C, Pun S et al (2016) Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. Oncologist 21:418-424
16 Zhang L, Liu Z, Hu KY et al (2015) Early myocardial damage assessment in dystrophinopathies using99Tcm-MIBI gated myocardial perfusion imaging. 10:1819-1827
17 Peli A, Camoni L, Zilioli V et al (2018) Attenuation correction in myocardial perfusion imaging affects the assessment of infarct size in women with previous inferior infarct. 39:1
18 Gomez J, Golzar Y, Fughhi I, Olusanya A, Doukky R (2018) The significance of post-stress decrease in left ventricular ejection fraction in patients undergoing regadenoson stress gated SPECT myocardial perfusion imaging. J Nucl Cardiol 25:1313-1323
19 Rosenberg SA, %J Cancer Treatment Reports (1977) Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. 61:1023-1027
20 Perez EA, Suman VJ, Davidson NE et al (2008) Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. 26:1231
21 Goel S, Liu J, Guo H et al (2019) Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity. JACC Heart Fail 7:795-804
22 Ho E, Brown A, Barrett P et al (2010) Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. 96:701-707
23 Yu W, Li SN, Chan GC, Ha SY, Wong SJ, Cheung YFJEHJCI (2013) Transmural strain and rotation gradient in survivors of childhood cancers. 14:175-182
24 Cerqueira MD, Weissman NJ, Vasken D et al (2002) Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. 9:240-245
25 McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM (2017) Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc Drugs Ther 31:63-75
26 Ferraro MP, Gimeno¬azquez E, Subirana I, Gómez M, Haematology ASJEJO (2019) Anthracycline﹊nduced cardiotoxicity in diffuse large Bヽell lymphoma: NT﹑roBNP and cardiovascular score for risk stratification. 102
27 Zelenetz AD, Gordon LI, Abramson JS et al (2019) NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. J Natl Compr Canc Netw 17:650-661
28 Thieblemont C, Bernard S, Meignan M, Molina T (2018) Optimizing initial therapy in DLBCL. Best Pract Res Clin Haematol 31:199-208
29 Bansal N, Amdani S, Lipshultz ER, Lipshultz SE (2017) Chemotherapy-induced cardiotoxicity in children. Expert Opin Drug Metab Toxicol 13:817-832
30 Veronese P, Hachul DT, Scanavacca MI et al (2018) Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer. PLoS One 13:e0196763
31 Porta-Sanchez A, Gilbert C, Spears D et al (2017) Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc 6
32 Heemskerk CPM, Pereboom M, van Stralen K et al (2018) Risk factors for QTc interval prolongation. Eur J Clin Pharmacol 74:183-191
33 Puppe J, van Ooyen D, Neise J et al (2017) Evaluation of QTc Interval Prolongation in Breast Cancer Patients after Treatment with Epirubicin, Cyclophosphamide, and Docetaxel and the Influence of Interobserver Variation. Breast Care (Basel) 12:40-44
34 Etchegoyen CV, Keller GA, Mrad S, Cheng S, Di Girolamo G (2017) Drug-induced QT Interval Prolongation in the Intensive Care Unit. Curr Clin Pharmacol 12:210-222
35 Renu K, V GA, P BT, Arunachalam S (2018) Molecular mechanism of doxorubicin-induced cardiomyopathy - An update. Eur J Pharmacol 818:241-253
36 Henninger C, Fritz G (2017) Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers. Cell Death Dis 8:e2564
37 Hahn VS, Lenihan DJ, Ky B (2014) Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc 3:e000665
38 Rochette L, Guenancia C, Gudjoncik A et al (2015) Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol Sci 36:326-348
39 Mukai M, Komori K, Oka T (2018) Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis. J Atheroscler Thromb 25:994-1002
40 Yin J, Guo J, Zhang Q et al (2018) Doxorubicin-induced mitophagy and mitochondrial damage is associated with dysregulation of the PINK1/parkin pathway. Toxicol In Vitro 51:1-10
41 Koleini N, Kardami E (2017) Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget 8:46663-46680
42 Ichikawa Y, Ghanefar M, Bayeva M et al (2014) Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest 124:617-630
43 Beller GA, Watson DD (1991) Physiological basis of myocardial perfusion imaging with the technetium 99m agents. Semin Nucl Med 21:173-181
44 Li J, Lu J, Zhou Y (2017) Mitochondrial-Targeted Molecular Imaging in Cardiac Disease. Biomed Res Int 2017:5246853
45 Bartholoma MD, Zhang S, Akurathi V et al (2015) (18)F-labeled rhodamines as potential myocardial perfusion agents: comparison of pharmacokinetic properties of several rhodamines. Nucl Med Biol 42:796-803
46 Sood N, Al Badarin F, Parker M et al (2013) Resting perfusion MPI-SPECT combined with cardiac 123I-mIBG sympathetic innervation imaging improves prediction of arrhythmic events in non-ischemic cardiomyopathy patients: sub-study from the ADMIRE-HF trial. J Nucl Cardiol 20:813-820